Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPS2-THRIVE
2006-001885-17Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity and atherosclerotic disease comparing Extended-release niacin + laropiprant with Placebo (2 arms). Primary endpoint: Time to first major vascular event. Started Jun 2006; status: completed.
02
Drugs
laropiprant + niacin
03
Conditions
cardiac morbidityatherosclerotic disease
Beyond the preview
Go deeper on 2006-001885-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001885-17.